Pfizer, Teva reach deal to allow generic Viagra
Fifteen years after Pfizer Inc.’s Viagra changed the sexual equation for older men, the blockbuster impotence drug is set to become available in a less expensive generic form as early as 2017.
Diseases
Articles
Lilly foe still testing Alzheimer’s theory where others failed
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
Lilly to spend another $700M in growing market for diabetes products
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
Lilly, other drugmakers itching to find new psoriasis treatment
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Lilly bets quality over quantity will pay off in diabetes battle
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Anthem rolls out new bonus system for docs
The Indianapolis-based health insurer expects to pay, on average, $3.50 per month for every patient enrolled in one of Anthem’s commercial health plans.
Alzheimer’s targeted in $45M government study grant
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
Lilly lung cancer drug raises patient survival in trial
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
Roche to cut local jobs after diabetes-care sales plunge
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Lilly drug for Alzheimer’s gets limited Medicare coverage
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Lilly wins patent lawsuit on J&J Alzheimer’s research
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
Lilly’s experimental diabetes drug helps patients lose weight
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
New law lets pharmacists provide pneumonia, HPV vaccines
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
Lilly study: 1 in 5 Alzheimer’s patients misdiagnosed
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Lilly taking hard look at Pfizer’s new Viagra strategy
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
New $100M plan to map human brain could boost Lilly
President Obama on Tuesday announced a campaign designed to develop treatments for some of the least understood brain disorders, an effort that could benefit health care giants Eli Lilly and Co. and others.
Lilly, Boehringer submit diabetes drug to FDA
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
Company taps sports market with bacteria-stalking chemical
Anderson-based Coeus Technology has invented a chemical that kills dangerous bacteria, including potentially deadly staph, by forming a germ-killing barrier that lasts two weeks to six months.
Testosterone for diabetes may be new market for Lilly, others
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.